Insight into Glenview Capital Management's Latest 13F Filing

Larry Robbins (Trades, Portfolio), a renowned figure in the investment world, recently submitted the 13F filing for the fourth quarter of 2024, shedding light on his strategic investment decisions. Robbins is the founder of Glenview Capital Management, established in 2000. The firm is known for its focus on delivering attractive absolute returns through deep fundamental research and individual security selection. Glenview Capital primarily invests in the U.S. market, with some exposure in Western Europe, managing assets through the Glenview Funds and the Glenview Opportunity Funds. Robbins' investment philosophy emphasizes a long/short approach and opportunistic, concentrated investments.

• Warning! GuruFocus has detected 6 Warning Signs with CVS.

Summary of New Buy

Larry Robbins (Trades, Portfolio) added a total of five stocks to his portfolio in the fourth quarter of 2024. The most significant addition was Centene Corp (NYSE:CNC), with 1,287,341 shares, accounting for 1.97% of the portfolio and a total value of $77.99 million. The second largest addition was Microsoft Corp (NASDAQ:MSFT), consisting of 103,649 shares, representing approximately 1.1% of the portfolio, with a total value of $43.69 million. The third largest addition was JBT Marel Corp (NYSE:JBTM), with 186,695 shares, accounting for 0.6% of the portfolio and a total value of $23.73 million.

Key Position Increases

Larry Robbins (Trades, Portfolio) also increased stakes in a total of 12 stocks. The most notable increase was in Alight Inc (NYSE:ALIT), with an additional 14,199,370 shares, bringing the total to 31,911,033 shares. This adjustment represents a significant 80.17% increase in share count, a 2.48% impact on the current portfolio, and a total value of $220.82 million. The second largest increase was in Dun & Bradstreet Holdings Inc (NYSE:DNB), with an additional 5,235,544 shares, bringing the total to 14,792,634. This adjustment represents a significant 54.78% increase in share count, with a total value of $184.32 million.

Summary of Sold Out

Larry Robbins (Trades, Portfolio) completely exited 12 holdings in the fourth quarter of 2024. Notable exits include Marvell Technology Inc (NASDAQ:MRVL), where Robbins sold all 1,165,121 shares, resulting in a -1.63% impact on the portfolio. Another significant exit was WESCO International Inc (NYSE:WCC), with the liquidation of all 274,794 shares, causing a -0.89% impact on the portfolio.

Key Position Reduces

Larry Robbins (Trades, Portfolio) also reduced positions in 15 stocks. The most significant change was a reduction in Corteva Inc (NYSE:CTVA) by 3,187,473 shares, resulting in a -60.79% decrease in shares and a -3.62% impact on the portfolio. The stock traded at an average price of $59.15 during the quarter and has returned 11.82% over the past three months and 12.39% year-to-date. Another notable reduction was in The Cigna Group (NYSE:CI) by 419,255 shares, resulting in a -39.87% reduction in shares and a -2.81% impact on the portfolio. The stock traded at an average price of $318.30 during the quarter and has returned -9.47% over the past three months and 5.74% year-to-date.

Portfolio Overview

As of the fourth quarter of 2024, Larry Robbins (Trades, Portfolio)' portfolio included 36 stocks. The top holdings were 13.56% in CVS Health Corp (NYSE:CVS), 11.12% in Global Payments Inc (NYSE:GPN), 9.05% in Tenet Healthcare Corp (NYSE:THC), 5.58% in Alight Inc (NYSE:ALIT), and 4.71% in Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

The holdings are mainly concentrated in eight of the 11 industries: Healthcare, Technology, Industrials, Consumer Cyclical, Basic Materials, Financial Services, Consumer Defensive, and Communication Services.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.